Strand and Pharmidex to collaborate to produce a new in silico technology for CNS drug discovery

23-Feb-2006

Strand Life Sciences announced that it has entered into a collaboration with Pharmidex. Both companies focus on providing solutions to facilitate the discovery and development of new medicines. Under the collaborative agreement both Strand and Pharmidex will promote each others existing offerings and will jointly develop new software to predict the ability of compounds to cross the blood-brain barrier (BBB). This effectively combines the in silico expertise of Strand with the BBB-focused offering of Pharmidex, which includes in vitro, ex vivo and in vivo methodologies.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances